SlideShare a Scribd company logo
1 of 12
C. DIFF DIARRHEA:
FIDAXOMICIN VS. VANCOMYCIN
OVMC LANDMARK TRIALS SERIES
Louie TJ, et al. "Fidaxomicin versus Vancomycin for
Clostridium difficile Infection". The New England Journal of
Medicine. 2011. 365(5):422-431.
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
BACKGROUND
 C. diff diarrhea is most common infectious entity in
nosocomial diarrhea
 Since 1990s>2x increase incidence of C.Diff
 Relapse rates are high
 New strains have emerged, including NAP1/BI/027
strain
 Fidaxomicin is a macrocylic antibiotic and has more
invitro activity against C.diff than Vancomycin
 Fidaxomicin has limited systemic absorption and
high fecal concentration
CLINICAL QUESTION
How does Fidaxomicin compare to Vancomycin in
terms of clinical cure for patients with Clostridium
difficile-associated diarrhea?
DESIGN
 Analysis: both modified intention-to-treat and per-protocol
 Trial Design: Prospective, multicenter, double-blind, randomized, parallel-group trial
 N=629
 Fidaxomicin (n=302)
 Vancomycin (n=327)
 Setting: 52 US sites and 15 Canadian sites
 Enrollment: May 2006 to August 2008
POPULATION
Inclusion Criteria
 Age ≥16 years
 Diarrhea positive for C. difficile toxin within 48h
prior to randomization
Exclusion Criteria
 Receiving other antibiotics effective against
CDAD (eg, rifaximin)
 Patients could receive ≤4 doses of
metronidazole/vancomycin within 24h prior to
randomization
 Likelihood of death within 72 hours from any
cause
 Toxic megacolon
 Past exposure to fidaxomicin
 Pregnancy/breastfeeding
 Inflammatory bowel disease
 >1 C.diff occurrence within 3 months of study
INTERVENTIONS
 Stratified according to whether current infection was FIRST EPISODE (primary occurrence) or SECOND
EPISODE (first recurrence) within 3 months before study start
 Received study medication orally each day for 10 days
 Fidaxomicin 200mg PO q12h with intervening matching doses of placebo
 Vancomycin 125mg PO q6h
 Assessed daily for clinical cure or failure during 10-day course of therapy
CRITICISMS/LIMITATIONS/FUNDING
 1st version of paper written by part-time employee of Optimer Pharmaceuticals
 Fidaxomicin is noninferior in rate of clinical cure and does have moderate recurrence reduction, but
is drastically more expensive (1 tab = $168, therapy course $3360)
 No report of PPI use, a risk factor for severe C.diff recurrence
 The treatment was mostly limited to the NAP1/BI/027 strain
 Unclear antibody levels to C. difficile toxin A, a value that may relate to risk of recurrence
 Excluded ill patients (eg patients with megacolon)
FUNDING:
Funded by Optimer Pharmaceuticals who manufactures Fidaxomicin
BOTTOM LINE
This Phase 3 trial showed that
Fidaxomicin was noninferior to
vancomycin in achieving rates of
clinical cure among patients
with Clostridium difficile-associated
diarrhea
Fidaxomicin was associated with a
significantly lower rate of
recurrence of C. difficile infection
associated with non-NAP1/BI/027
strain
Guidelines -- IDSA/SHE CDAD (2010)
Discontinue treatment with the antibiotic thought to be associated with CDAD
occurrence as soon as possible (A-II)
Start empirical treatment in severe or complicated CDAD as soon as suspected (C-III)
Avoid antiperistaltic agents (C-III)
Metronidazole 500 mg po TID for 10-14 days for initial episode of mild-to-moderate
CDAD (A-I)
Vancomycin 125 mg po QID for 10-14 days for initial episode of severe CDAD (B-I)
Vancomycin 500 mg PO QID +/- metronidazole 500 mg IV q8h for severe,
complicated CDAD (C-III)
--If ileus, vancomycin 500 mg in 100 mL NS PR q6h as a retention enema
≥2nd CDAD recurrence with taper or pulse of vancomycin (B-III)
Avoid metronidazole after the first recurrence of CDAD, including as a long-term
agent, beacause of the risk of neurotoxicity (B-II)
BOARD-LIKE QUESTION
A 41 yo woman is hospitalized for severe
cellulitis. She is treated with Vanc/Zosyn, and
discharged on PO Clindamycin. However, 5 days
later he develops a fever and diarrhea, described
as 5-8 liquid bowel movements over the last 24
hours. Medications include Metformin for DM2,
Amlodipine for HTN.
Physical exam:
T 38, HR 107, BP 148/71
Abdomen: B+, soft, mildly tender diffusely
Labs:
WBC 18K, Creatinine 1.7 (baseline 0.9)
Stool PCR shows C.diff
Which of the following is the most appropriate
treatment?
A. Oral Metronidazole
B. Oral Fidaxomicin
C. IV Vanc + IV Metronidazole
D. Oral Vanc + IV Vanc
E. Oral Vanc + Oral metronidazole
BOARD-LIKE QUESTION
ANSWER
Which of the following is the most appropriate
oral treatment?
A. Oral Metronidazole
B. Oral Fidaxomicin
C. IV Vanc + IV Metronidazole
D. Oral Vanc + IV Vanc
E. Oral Vanc + Oral metronidazole
Educational Objective:
Treat a severe case of Clostridium
difficile infection.
Key Point:
- Severe Clostridium difficile infection should be
treated with oral vancomycin.
- Oral Fidaxomicin non-inferior to oral
Vancomycin
- Severe CDI is defined by the Infectious
Diseases Society of America as a leukocyte
count of 15,000/µL (15 × 109/L) or greater and
a serum creatinine level greater than 1.5 times
the baseline level
REFERENCES
 Louie TJ, et al. "Fidaxomicin versus Vancomycin
for Clostridium difficile Infection". The New
England Journal of Medicine. 2011. 365(5):422-
431.
 Brain, L. P. (n.d.). Fidaxomicin in C. difficile
Diarrhea.
https://www.wikijournalclub.org/w/index.php?tit
le=Fidaxomicin_in_C._difficile_Diarrhea

More Related Content

What's hot

Management of infections in immunocompromised patients
Management of infections in immunocompromised patientsManagement of infections in immunocompromised patients
Management of infections in immunocompromised patients
Sujay Iyer
 
Optimizing antibiotic therapy in icu setting
Optimizing antibiotic therapy in icu settingOptimizing antibiotic therapy in icu setting
Optimizing antibiotic therapy in icu setting
Mahen Kothalawala
 
Fungal infections in hematology patients: advances in prophylaxis and treatment
Fungal infections in hematology patients: advances in prophylaxis and treatmentFungal infections in hematology patients: advances in prophylaxis and treatment
Fungal infections in hematology patients: advances in prophylaxis and treatment
spa718
 
Fungal infections in critical care(cases)
Fungal infections in critical care(cases)Fungal infections in critical care(cases)
Fungal infections in critical care(cases)
fungalinfection
 

What's hot (20)

nomenclature of monoclonal antibodies
nomenclature of monoclonal antibodies nomenclature of monoclonal antibodies
nomenclature of monoclonal antibodies
 
Clostridium difficile: C. diff is more difficult than ever - presentation by ...
Clostridium difficile: C. diff is more difficult than ever - presentation by ...Clostridium difficile: C. diff is more difficult than ever - presentation by ...
Clostridium difficile: C. diff is more difficult than ever - presentation by ...
 
Covid19, varient overview
Covid19,  varient  overviewCovid19,  varient  overview
Covid19, varient overview
 
Management of infections in immunocompromised patients
Management of infections in immunocompromised patientsManagement of infections in immunocompromised patients
Management of infections in immunocompromised patients
 
Rational use of Antibiotics
Rational use of AntibioticsRational use of Antibiotics
Rational use of Antibiotics
 
Principles of Antibiotic Use in ICU
Principles of Antibiotic Use in ICUPrinciples of Antibiotic Use in ICU
Principles of Antibiotic Use in ICU
 
Antifungals in icu
Antifungals in icuAntifungals in icu
Antifungals in icu
 
Optimizing antibiotic therapy in icu setting
Optimizing antibiotic therapy in icu settingOptimizing antibiotic therapy in icu setting
Optimizing antibiotic therapy in icu setting
 
Febrile neutropenia
Febrile neutropeniaFebrile neutropenia
Febrile neutropenia
 
HAP VAP CHALLENGES
HAP VAP CHALLENGESHAP VAP CHALLENGES
HAP VAP CHALLENGES
 
Fungal infections in hematology patients: advances in prophylaxis and treatment
Fungal infections in hematology patients: advances in prophylaxis and treatmentFungal infections in hematology patients: advances in prophylaxis and treatment
Fungal infections in hematology patients: advances in prophylaxis and treatment
 
Multi-trait modeling in polygenic scores, journal club talk at Debora Marks lab
Multi-trait modeling in polygenic scores, journal club talk at Debora Marks labMulti-trait modeling in polygenic scores, journal club talk at Debora Marks lab
Multi-trait modeling in polygenic scores, journal club talk at Debora Marks lab
 
Hodgkin's Lymphoma: Treatment Update
Hodgkin's Lymphoma: Treatment UpdateHodgkin's Lymphoma: Treatment Update
Hodgkin's Lymphoma: Treatment Update
 
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIRFebrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
 
The New War on Bugs: Crafting an Effective Antibiotic Stewardship Program (Ar...
The New War on Bugs: Crafting an Effective Antibiotic Stewardship Program (Ar...The New War on Bugs: Crafting an Effective Antibiotic Stewardship Program (Ar...
The New War on Bugs: Crafting an Effective Antibiotic Stewardship Program (Ar...
 
Antimicrobial Resistance - Hemant Kanase
Antimicrobial Resistance - Hemant KanaseAntimicrobial Resistance - Hemant Kanase
Antimicrobial Resistance - Hemant Kanase
 
Micafungin vs. caspofungin in hsct
Micafungin vs. caspofungin in hsctMicafungin vs. caspofungin in hsct
Micafungin vs. caspofungin in hsct
 
Fungal infections in critical care(cases)
Fungal infections in critical care(cases)Fungal infections in critical care(cases)
Fungal infections in critical care(cases)
 
CATHETER RELATED BLOOD STREAM INFECTION
CATHETER RELATED BLOOD STREAM INFECTIONCATHETER RELATED BLOOD STREAM INFECTION
CATHETER RELATED BLOOD STREAM INFECTION
 
Final post kt infection
Final post kt infectionFinal post kt infection
Final post kt infection
 

Viewers also liked

BP#62_p40-43 fine art nudes
BP#62_p40-43 fine art nudesBP#62_p40-43 fine art nudes
BP#62_p40-43 fine art nudes
Lynn Gail
 

Viewers also liked (20)

COLONPREV
COLONPREVCOLONPREV
COLONPREV
 
Jupiter Trial
Jupiter TrialJupiter Trial
Jupiter Trial
 
GI Bleed
GI BleedGI Bleed
GI Bleed
 
Ephesus
EphesusEphesus
Ephesus
 
Courage Trial
Courage TrialCourage Trial
Courage Trial
 
STOPAH
STOPAHSTOPAH
STOPAH
 
Slidesharepresentation.carol casas
Slidesharepresentation.carol casasSlidesharepresentation.carol casas
Slidesharepresentation.carol casas
 
SALT-E 5
SALT-E 5SALT-E 5
SALT-E 5
 
SALT-E 3
SALT-E 3SALT-E 3
SALT-E 3
 
SALT-E 2
SALT-E 2SALT-E 2
SALT-E 2
 
SALT-E 6
SALT-E 6SALT-E 6
SALT-E 6
 
SALT-E 4
SALT-E 4SALT-E 4
SALT-E 4
 
Zinplava
ZinplavaZinplava
Zinplava
 
Manual de redes
Manual de redesManual de redes
Manual de redes
 
Presentacion rosa
Presentacion rosaPresentacion rosa
Presentacion rosa
 
Node child process
Node child processNode child process
Node child process
 
Parenting stress conceptual figure
Parenting stress conceptual figureParenting stress conceptual figure
Parenting stress conceptual figure
 
Listex general presentation (Feb 2017)
Listex general presentation (Feb 2017)Listex general presentation (Feb 2017)
Listex general presentation (Feb 2017)
 
Affirm Trial
Affirm TrialAffirm Trial
Affirm Trial
 
BP#62_p40-43 fine art nudes
BP#62_p40-43 fine art nudesBP#62_p40-43 fine art nudes
BP#62_p40-43 fine art nudes
 

Similar to Fidaxomicin in cdiff

Update On Antifungals,Grand Round
Update On Antifungals,Grand RoundUpdate On Antifungals,Grand Round
Update On Antifungals,Grand Round
Dang Thanh Tuan
 
Treating Clostridium Difficile Infection With Faecal Microbiota Transplantation
Treating Clostridium Difficile Infection With Faecal Microbiota TransplantationTreating Clostridium Difficile Infection With Faecal Microbiota Transplantation
Treating Clostridium Difficile Infection With Faecal Microbiota Transplantation
Edith Ngobi
 
Periop conference clostridium difficile sep 11 2010
Periop conference   clostridium difficile sep 11 2010Periop conference   clostridium difficile sep 11 2010
Periop conference clostridium difficile sep 11 2010
Maureen Spencer, RN, M.Ed.
 
Polimixina b y falla renal
Polimixina b y falla renalPolimixina b y falla renal
Polimixina b y falla renal
eduardo de avila
 

Similar to Fidaxomicin in cdiff (20)

Vancomycin vs Metronidazole in C.Diff
Vancomycin vs Metronidazole in C.DiffVancomycin vs Metronidazole in C.Diff
Vancomycin vs Metronidazole in C.Diff
 
Clostridium difficile infection
Clostridium difficile infectionClostridium difficile infection
Clostridium difficile infection
 
C.Diff
C.DiffC.Diff
C.Diff
 
Clostridium difficile
Clostridium difficileClostridium difficile
Clostridium difficile
 
Jornal Club Evaluation (PID).pptx
Jornal Club Evaluation (PID).pptxJornal Club Evaluation (PID).pptx
Jornal Club Evaluation (PID).pptx
 
ventilator Associated Pneumonia -By Dr.Tinku Joseph
ventilator Associated Pneumonia -By Dr.Tinku Josephventilator Associated Pneumonia -By Dr.Tinku Joseph
ventilator Associated Pneumonia -By Dr.Tinku Joseph
 
Update On Antifungals,Grand Round
Update On Antifungals,Grand RoundUpdate On Antifungals,Grand Round
Update On Antifungals,Grand Round
 
Antibiotics dr alsalheen alraied
Antibiotics dr alsalheen alraiedAntibiotics dr alsalheen alraied
Antibiotics dr alsalheen alraied
 
Selecting Antifungal Agents in ICU
Selecting Antifungal Agents in ICUSelecting Antifungal Agents in ICU
Selecting Antifungal Agents in ICU
 
Antibiotic associated diarrhea & Clostridium difficile infection
Antibiotic associated diarrhea & Clostridium difficile infectionAntibiotic associated diarrhea & Clostridium difficile infection
Antibiotic associated diarrhea & Clostridium difficile infection
 
Treating Clostridium Difficile Infection With Faecal Microbiota Transplantation
Treating Clostridium Difficile Infection With Faecal Microbiota TransplantationTreating Clostridium Difficile Infection With Faecal Microbiota Transplantation
Treating Clostridium Difficile Infection With Faecal Microbiota Transplantation
 
clostridium diarrhea
clostridium diarrheaclostridium diarrhea
clostridium diarrhea
 
Periop conference clostridium difficile sep 11 2010
Periop conference   clostridium difficile sep 11 2010Periop conference   clostridium difficile sep 11 2010
Periop conference clostridium difficile sep 11 2010
 
Dermatology MCQ and AAFP.pptx
Dermatology MCQ and AAFP.pptxDermatology MCQ and AAFP.pptx
Dermatology MCQ and AAFP.pptx
 
Antifungal Strategies in the Intensive Care Units
Antifungal Strategies in the Intensive Care UnitsAntifungal Strategies in the Intensive Care Units
Antifungal Strategies in the Intensive Care Units
 
CDI 2019
CDI 2019CDI 2019
CDI 2019
 
Polimixina b y falla renal
Polimixina b y falla renalPolimixina b y falla renal
Polimixina b y falla renal
 
Mohp Egyptian protocol for covid19 november 2020
Mohp Egyptian protocol for covid19 november 2020Mohp Egyptian protocol for covid19 november 2020
Mohp Egyptian protocol for covid19 november 2020
 
Rifaximin for Recurrent Clostridium Difficile Infections
Rifaximin for Recurrent Clostridium Difficile InfectionsRifaximin for Recurrent Clostridium Difficile Infections
Rifaximin for Recurrent Clostridium Difficile Infections
 
clostridium Diarrhea
clostridium Diarrheaclostridium Diarrhea
clostridium Diarrhea
 

More from Isabella Nga Lai (11)

UKPDS
UKPDSUKPDS
UKPDS
 
DCCT
DCCTDCCT
DCCT
 
ACCORD
ACCORDACCORD
ACCORD
 
RABBIT 2
RABBIT 2RABBIT 2
RABBIT 2
 
SONIC
SONICSONIC
SONIC
 
CYCLOPS
CYCLOPSCYCLOPS
CYCLOPS
 
ATN
ATNATN
ATN
 
ACT
ACTACT
ACT
 
SPARCL
SPARCLSPARCL
SPARCL
 
CORTICUS
CORTICUSCORTICUS
CORTICUS
 
Nice-Sugar
Nice-SugarNice-Sugar
Nice-Sugar
 

Recently uploaded

The basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxThe basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptx
heathfieldcps1
 
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
中 央社
 

Recently uploaded (20)

The Ball Poem- John Berryman_20240518_001617_0000.pptx
The Ball Poem- John Berryman_20240518_001617_0000.pptxThe Ball Poem- John Berryman_20240518_001617_0000.pptx
The Ball Poem- John Berryman_20240518_001617_0000.pptx
 
BỘ LUYỆN NGHE TIẾNG ANH 8 GLOBAL SUCCESS CẢ NĂM (GỒM 12 UNITS, MỖI UNIT GỒM 3...
BỘ LUYỆN NGHE TIẾNG ANH 8 GLOBAL SUCCESS CẢ NĂM (GỒM 12 UNITS, MỖI UNIT GỒM 3...BỘ LUYỆN NGHE TIẾNG ANH 8 GLOBAL SUCCESS CẢ NĂM (GỒM 12 UNITS, MỖI UNIT GỒM 3...
BỘ LUYỆN NGHE TIẾNG ANH 8 GLOBAL SUCCESS CẢ NĂM (GỒM 12 UNITS, MỖI UNIT GỒM 3...
 
UChicago CMSC 23320 - The Best Commit Messages of 2024
UChicago CMSC 23320 - The Best Commit Messages of 2024UChicago CMSC 23320 - The Best Commit Messages of 2024
UChicago CMSC 23320 - The Best Commit Messages of 2024
 
philosophy and it's principles based on the life
philosophy and it's principles based on the lifephilosophy and it's principles based on the life
philosophy and it's principles based on the life
 
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjj
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjjStl Algorithms in C++ jjjjjjjjjjjjjjjjjj
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjj
 
The Last Leaf, a short story by O. Henry
The Last Leaf, a short story by O. HenryThe Last Leaf, a short story by O. Henry
The Last Leaf, a short story by O. Henry
 
Championnat de France de Tennis de table/
Championnat de France de Tennis de table/Championnat de France de Tennis de table/
Championnat de France de Tennis de table/
 
II BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING II
II BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING IIII BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING II
II BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING II
 
How to Analyse Profit of a Sales Order in Odoo 17
How to Analyse Profit of a Sales Order in Odoo 17How to Analyse Profit of a Sales Order in Odoo 17
How to Analyse Profit of a Sales Order in Odoo 17
 
The basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxThe basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptx
 
Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45
Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45
Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45
 
Word Stress rules esl .pptx
Word Stress rules esl               .pptxWord Stress rules esl               .pptx
Word Stress rules esl .pptx
 
Incoming and Outgoing Shipments in 2 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 2 STEPS Using Odoo 17Incoming and Outgoing Shipments in 2 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 2 STEPS Using Odoo 17
 
An overview of the various scriptures in Hinduism
An overview of the various scriptures in HinduismAn overview of the various scriptures in Hinduism
An overview of the various scriptures in Hinduism
 
24 ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH SỞ GIÁO DỤC HẢI DƯ...
24 ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH SỞ GIÁO DỤC HẢI DƯ...24 ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH SỞ GIÁO DỤC HẢI DƯ...
24 ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH SỞ GIÁO DỤC HẢI DƯ...
 
Dementia (Alzheimer & vasular dementia).
Dementia (Alzheimer & vasular dementia).Dementia (Alzheimer & vasular dementia).
Dementia (Alzheimer & vasular dementia).
 
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽會考英聽
 
Mattingly "AI and Prompt Design: LLMs with Text Classification and Open Source"
Mattingly "AI and Prompt Design: LLMs with Text Classification and Open Source"Mattingly "AI and Prompt Design: LLMs with Text Classification and Open Source"
Mattingly "AI and Prompt Design: LLMs with Text Classification and Open Source"
 
IPL Online Quiz by Pragya; Question Set.
IPL Online Quiz by Pragya; Question Set.IPL Online Quiz by Pragya; Question Set.
IPL Online Quiz by Pragya; Question Set.
 
Operations Management - Book1.p - Dr. Abdulfatah A. Salem
Operations Management - Book1.p  - Dr. Abdulfatah A. SalemOperations Management - Book1.p  - Dr. Abdulfatah A. Salem
Operations Management - Book1.p - Dr. Abdulfatah A. Salem
 

Fidaxomicin in cdiff

  • 1. C. DIFF DIARRHEA: FIDAXOMICIN VS. VANCOMYCIN OVMC LANDMARK TRIALS SERIES Louie TJ, et al. "Fidaxomicin versus Vancomycin for Clostridium difficile Infection". The New England Journal of Medicine. 2011. 365(5):422-431.
  • 2. Fidaxomicin versus Vancomycin for Clostridium difficile Infection
  • 3. BACKGROUND  C. diff diarrhea is most common infectious entity in nosocomial diarrhea  Since 1990s>2x increase incidence of C.Diff  Relapse rates are high  New strains have emerged, including NAP1/BI/027 strain  Fidaxomicin is a macrocylic antibiotic and has more invitro activity against C.diff than Vancomycin  Fidaxomicin has limited systemic absorption and high fecal concentration
  • 4. CLINICAL QUESTION How does Fidaxomicin compare to Vancomycin in terms of clinical cure for patients with Clostridium difficile-associated diarrhea?
  • 5. DESIGN  Analysis: both modified intention-to-treat and per-protocol  Trial Design: Prospective, multicenter, double-blind, randomized, parallel-group trial  N=629  Fidaxomicin (n=302)  Vancomycin (n=327)  Setting: 52 US sites and 15 Canadian sites  Enrollment: May 2006 to August 2008
  • 6. POPULATION Inclusion Criteria  Age ≥16 years  Diarrhea positive for C. difficile toxin within 48h prior to randomization Exclusion Criteria  Receiving other antibiotics effective against CDAD (eg, rifaximin)  Patients could receive ≤4 doses of metronidazole/vancomycin within 24h prior to randomization  Likelihood of death within 72 hours from any cause  Toxic megacolon  Past exposure to fidaxomicin  Pregnancy/breastfeeding  Inflammatory bowel disease  >1 C.diff occurrence within 3 months of study
  • 7. INTERVENTIONS  Stratified according to whether current infection was FIRST EPISODE (primary occurrence) or SECOND EPISODE (first recurrence) within 3 months before study start  Received study medication orally each day for 10 days  Fidaxomicin 200mg PO q12h with intervening matching doses of placebo  Vancomycin 125mg PO q6h  Assessed daily for clinical cure or failure during 10-day course of therapy
  • 8. CRITICISMS/LIMITATIONS/FUNDING  1st version of paper written by part-time employee of Optimer Pharmaceuticals  Fidaxomicin is noninferior in rate of clinical cure and does have moderate recurrence reduction, but is drastically more expensive (1 tab = $168, therapy course $3360)  No report of PPI use, a risk factor for severe C.diff recurrence  The treatment was mostly limited to the NAP1/BI/027 strain  Unclear antibody levels to C. difficile toxin A, a value that may relate to risk of recurrence  Excluded ill patients (eg patients with megacolon) FUNDING: Funded by Optimer Pharmaceuticals who manufactures Fidaxomicin
  • 9. BOTTOM LINE This Phase 3 trial showed that Fidaxomicin was noninferior to vancomycin in achieving rates of clinical cure among patients with Clostridium difficile-associated diarrhea Fidaxomicin was associated with a significantly lower rate of recurrence of C. difficile infection associated with non-NAP1/BI/027 strain Guidelines -- IDSA/SHE CDAD (2010) Discontinue treatment with the antibiotic thought to be associated with CDAD occurrence as soon as possible (A-II) Start empirical treatment in severe or complicated CDAD as soon as suspected (C-III) Avoid antiperistaltic agents (C-III) Metronidazole 500 mg po TID for 10-14 days for initial episode of mild-to-moderate CDAD (A-I) Vancomycin 125 mg po QID for 10-14 days for initial episode of severe CDAD (B-I) Vancomycin 500 mg PO QID +/- metronidazole 500 mg IV q8h for severe, complicated CDAD (C-III) --If ileus, vancomycin 500 mg in 100 mL NS PR q6h as a retention enema ≥2nd CDAD recurrence with taper or pulse of vancomycin (B-III) Avoid metronidazole after the first recurrence of CDAD, including as a long-term agent, beacause of the risk of neurotoxicity (B-II)
  • 10. BOARD-LIKE QUESTION A 41 yo woman is hospitalized for severe cellulitis. She is treated with Vanc/Zosyn, and discharged on PO Clindamycin. However, 5 days later he develops a fever and diarrhea, described as 5-8 liquid bowel movements over the last 24 hours. Medications include Metformin for DM2, Amlodipine for HTN. Physical exam: T 38, HR 107, BP 148/71 Abdomen: B+, soft, mildly tender diffusely Labs: WBC 18K, Creatinine 1.7 (baseline 0.9) Stool PCR shows C.diff Which of the following is the most appropriate treatment? A. Oral Metronidazole B. Oral Fidaxomicin C. IV Vanc + IV Metronidazole D. Oral Vanc + IV Vanc E. Oral Vanc + Oral metronidazole
  • 11. BOARD-LIKE QUESTION ANSWER Which of the following is the most appropriate oral treatment? A. Oral Metronidazole B. Oral Fidaxomicin C. IV Vanc + IV Metronidazole D. Oral Vanc + IV Vanc E. Oral Vanc + Oral metronidazole Educational Objective: Treat a severe case of Clostridium difficile infection. Key Point: - Severe Clostridium difficile infection should be treated with oral vancomycin. - Oral Fidaxomicin non-inferior to oral Vancomycin - Severe CDI is defined by the Infectious Diseases Society of America as a leukocyte count of 15,000/µL (15 × 109/L) or greater and a serum creatinine level greater than 1.5 times the baseline level
  • 12. REFERENCES  Louie TJ, et al. "Fidaxomicin versus Vancomycin for Clostridium difficile Infection". The New England Journal of Medicine. 2011. 365(5):422- 431.  Brain, L. P. (n.d.). Fidaxomicin in C. difficile Diarrhea. https://www.wikijournalclub.org/w/index.php?tit le=Fidaxomicin_in_C._difficile_Diarrhea